Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsement (GILD)

REUTERS/Suzanne Plunkett Gilead is spending$12 billion to buy Kite Pharma, a biotech that has no approved therapies yet. The drugmaker's therapy that's a few months away from a possible approval isahighly personalized cancer treatments calledCAR T-cell therapy. It's a formof cancer immunotherapy — or atherapy that harnesses the body's immune system to take on cancer cells. For Gilead, which is known for its HIV and hepatitis C medications, this is anentirely new area of cancer development. "Th...